Table 1.

Mean (+ SD) novelty seeking and harm avoidance scores dependent on an individual's COMT and DRD2 genotype

DRD2	COMT	N	Mean (± SD)
Clinical Sample 1
Novelty seeking
A1 absent	Val absent	19	56.2 ± 14.0
	Val present	69	51.8 ± 18.3
A1 present	Val absent	19	47.4 ± 13.6
	Val present	39	51.0 ± 15.1
DRD2 main effect			F (1,142) = 2.38, p = 0.125
COMT main effect			F (1,142) = 0.015, p = 0.901
DRD2 × COMT			F (1,142) = 1.62, p = 0.206
Harm avoidance
A1 absent	Val absent	19	70.8 ± 15.9
	Val present	69	67.0 ± 21.0
A1 present	Val absent	19	66.9 ± 23.4
	Val present	39	66.3 ± 19.8
DRD2 main effect			F (1,142) = 0.356, p = 0.552
COMT main effect			F (1,142) = 0.319, p = 0.573
DRD2 × COMT			F (1,142) = 0.165, p = 0.685
Clinical Sample 2
Novelty seeking
A1 absent	Val absent	16	48.3 ± 18.5
	Val present	62	47.9 ± 15.9
A1 present	Val absent	14	46.4 ± 12.5
	Val present	54	47.9 ± 14.0
DRD2 main effect			F (1,142) = 0.087, p = 0.769
COMT main effect			F (1,142) = 0.027, p = 0.870
DRD2 × COMT			F (1,142) = 0.088, p = 0.767
Harm avoidance
A1 absent	Val absent	16	70.7 ± 18.1
	Val present	62	72.3 ± 15.9
A1 present	Val absent	14	73.1 ± 17.5
	Val present	54	69.3 ± 22.1
DRD2 main effect			F (1,142) = 0.008, p = 0.928
COMT main effect			F (1,142) = 0.082, p = 0.775
DRD2 × COMT			F (1,142) = 0.489, p = 0.485